Literature DB >> 11036061

Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates.

F J Schmitz1, A C Fluit, D Hafner, A Beeck, M Perdikouli, M Boos, S Scheuring, J Verhoef, K Köhrer, C Von Eiff.   

Abstract

A relationship between resistance to methicillin and resistance to fluoroquinolones, rifampin, and mupirocin has been described for Staphylococcus aureus. Differences in resistance rates may be explainable by a higher spontaneous mutation rate (MR) or a faster development of resistance (DIFF) in methicillin-resistant S. aureus (MRSA). No differences in MR, DIFF, and mutations in grlA and gyrA were detected between methicillin-susceptible S. aureus and MRSA. The higher resistance rates in MRSA are not the result of hypermutability of target genes or a faster emergence of different mutations and may be the consequence of clonal spread of multiresistant MRSA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036061      PMCID: PMC101641          DOI: 10.1128/AAC.44.11.3229-3231.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus.

Authors:  T A Wichelhaus; V Schäfer; V Brade; B Böddinghaus
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Staphylococcus aureus small colony variants: rate of selection and MIC values compared to wild-type strains, using ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin.

Authors:  Franz-Josef Schmitz; Christof von Eiff; Mechthild Gondolf; Ad C. Fluit; Jan Verhoef; Georg Peters; Ulrich Hadding; Hans-Peter Heinz; Mark E. Jones
Journal:  Clin Microbiol Infect       Date:  1999-06       Impact factor: 8.067

3.  Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.

Authors:  F J Schmitz; B Hofmann; B Hansen; S Scheuring; M Lückefahr; M Klootwijk; J Verhoef; A Fluit; H P Heinz; K Köhrer; M E Jones
Journal:  J Antimicrob Chemother       Date:  1998-04       Impact factor: 5.790

4.  Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.

Authors:  F J Schmitz; A C Fluit; S Brisse; J Verhoef; K Köhrer; D Milatovic
Journal:  FEMS Immunol Med Microbiol       Date:  1999-12

5.  High mutation frequencies among Escherichia coli and Salmonella pathogens.

Authors:  J E LeClerc; B Li; W L Payne; T A Cebula
Journal:  Science       Date:  1996-11-15       Impact factor: 47.728

6.  Insertional inactivation of staphylococcal methicillin resistance by Tn551.

Authors:  B Berger-Bächi
Journal:  J Bacteriol       Date:  1983-04       Impact factor: 3.490

Review 7.  The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice.

Authors:  B D Cookson
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

8.  The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals.

Authors:  F J Schmitz; E Lindenlauf; B Hofmann; A C Fluit; J Verhoef; H P Heinz; M E Jones
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790

9.  Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus.

Authors:  H Aubry-Damon; C J Soussy; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.

Authors:  L Ferrero; B Cameron; J Crouzet
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  18 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

Review 2.  [Antibacterial photodynamic therapy. A new treatment for superficial bacterial infections?].

Authors:  T Maisch; R-M Szeimies; N Lehn; C Abels
Journal:  Hautarzt       Date:  2005-11       Impact factor: 0.751

3.  Antistaphylococcal activity of DX-619 alone and in combination with vancomycin, teicoplanin, and linezolid assessed by time-kill synergy testing.

Authors:  Kim Credito; Genrong Lin; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

4.  Identification of point mutations in clinical Staphylococcus aureus strains that produce small-colony variants auxotrophic for menadione.

Authors:  Melissa A Dean; Randall J Olsen; S Wesley Long; Adriana E Rosato; James M Musser
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

5.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

6.  Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies.

Authors:  Glenn A Pankuch; Gengrong Lin; Dianne B Hoellman; Caryn E Good; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

7.  Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.

Authors:  Tatiana Bogdanovich; Duygu Esel; Linda M Kelly; Bülent Bozdogan; Kim Credito; Gengrong Lin; Kathy Smith; Lois M Ednie; Dianne B Hoellman; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

8.  Biphenylthiazole antibiotics with an oxadiazole linker: An approach to improve physicochemical properties and oral bioavailability.

Authors:  Mohamed Hagras; Youssef A Hegazy; Amr H Elkabbany; Haroon Mohammad; Adel Ghiaty; Tamer M Abdelghany; Mohamed N Seleem; Abdelrahman S Mayhoub
Journal:  Eur J Med Chem       Date:  2017-10-19       Impact factor: 6.514

9.  Role of mutS and mutL genes in hypermutability and recombination in Staphylococcus aureus.

Authors:  Anne-Laure Prunier; Roland Leclercq
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

10.  In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.

Authors:  Christopher K Murphy; Steve Mullin; Marcia S Osburne; John van Duzer; Jim Siedlecki; Xiang Yu; Kathy Kerstein; Michael Cynamon; David M Rothstein
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.